uptodate.com/contents/guillain-barre-syndrome-in-adults

Sejvar JJ, BaughmanAL, Wise M, and Morgan OW. Population Incidence of Guillain-Barré Syndrome: ASystematic Review and Meta-Analysis Neuroepidemiology. 2011; 36(2): 123–133.

Baker MG, Kvalsvig A,Zhang J, Lake R,  Sears A and Wilson N.Declining Guillain-Barré Syndrome after Campylobacteriosis Control, NewZealand, 1988–2010. Emerg Infect Dis. 2012;18(2):226-233.

Salmon DA, Proschan M,Forshee R, Gargiullo P, Bleser W et al.  Association between Guillain-Barré syndrome andinfluenza A (H1N1) 2009 monovalent inactivated vaccines in the USA: ameta-analysis. Lancet. 2013;381(9876):1461. Epub 2013 Mar 13.

Grave C, Boucheron P,Rudant J, Mikaeloff Y, Tubert-Bitter P, Escolano S et al. Seasonal influenzavaccine and Guillain-Barré syndrome. Neurology 2020; 94:2168-2179.

Kwong JC, Vasa PP,Campitelli MA, et al. Risk of Guillain-Barré syndrome after seasonal influenzavaccination and influenza health-care encounters: a self-controlled study. TheLancet Infectious Diseases. 2013; 13: 769-76.

Goud R, Lufkin B,Duffy J, Whitaker B, Wong H-L et al. Risk of Guillain-Barré Syndrome Following Recombinant Zoster Vaccine inMedicare Beneficiaries. JAMA Intern Med. 2021 Nov 1;181(12):1–8.

Kang JH, Sheu JJ, andLin HC. Increased Risk of Guillain-barre’ Syndrome following Recent HerpesZoster: A Population-Based Study across Taiwan. Clinical Infectious Diseases2010; 51(5):525–530.  

Anderson TC, Leung JW,Harpaz R and Dooling KL. Risk of Guillain-Barré syndrome following herpeszoster, United States, 2010–2018. HUMAN VACCINES & IMMUNOTHERAPEUTICS 2021,VOL. 17, NO. 12, 5304–5310

Abara We, Gee J,Marquez P, Woo J, Myers TR. Reports of Guillain-Barré Syndrome After COVID-19Vaccination in the United States. JAMA Network Open. 2023;6(2): e2253845.

Patone M, HandunnetthiL, Saatci D, Pan J, Katikireddi SV et al. Neurological complications afterfirst dose of COVID-19 vaccines and SARS-CoV-2 infection. Nat Med 27, 2144–2153(2021). doi.org/10.1038/s41591-021-01556-7

Lloyd P. Evaluation ofGuillain-Barré Syndrome (GBS) following Respiratory Syncytial Virus (RSV)Vaccination Among Adults 65 Years and Older. ACIP meeting Oct 23-24, 2024. cdc.gov/acip/downloads/slides-2024-10-23-24/05-RSV-Adult-Lloyd-508.pdf

Melgar M and BrittonA. RSV Vaccination in Adults: Work Group Interpretations. ACIP meeting Oct23-24, 2024. cdc.gov/acip/downloads/slides-2024-10-23-24/06-RSV-Adult-Melgar-508.pdf

Baxter R, Lewis N,Bakshi N, Vellozzi C and Klein NP. Recurrent Guillain-Barre syndrome followingvaccination. Clinical infectious diseases: 2012; 54: 800-4.

Kuitwaard K, vanKoningsveld R, Ruts L, Jacobs BC and van Doorn PA. Recurrent Guillain–Barrésyndrome. Journal of Neurology, Neurosurgery & Psychiatry. 2009; 80: 56-9.

Wijdicks EF, FletcherDD and Lawn ND. Influenza vaccine and the risk of relapse of Guillain–Barresyndrome. Neurology. 2000; 55: 452-3.

Pritchard J, MukherjeeR and Hughes R. Risk of relapse of Guillain-Barré syndrome or chronicinflammatory demyelinating polyradiculoneuropathy following immunisation.Journal of Neurology, Neurosurgery & Psychiatry. 2002; 73: 348-9.

Ben David SS, PotasmanI and Rahamim-Cohen D.  Rate of RecurrentGuillain-Barré Syndrome After mRNA COVID-19 Vaccine BNT162b2. JAMA Neurol.2021;78(11): 1409-1411.

Yong Chen, JinlinZhang, Xuhua Chu,  Yuanling Xu,  Fubao Ma. Vaccines and the risk of Guillain‑Barré syndrome.European Journal of Epidemiology (2020) 35:363–370.

Holtz BO, Grimm A,Axer H. Patients' attitude towards vaccination after Guillain Barré syndrome.Health Science Reports 2021,4 (4). doi.org/10.1002/hsr2.469 COVID-19 in NewZealand 

‍